Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Ann Rheum Dis · 2018 · PMC6104680 · PMID 29853453

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

showed a trendno p-value reported

As previously reported, primary clinical data from the faSScinate trial showed a trend of benefit in favour of TCZ for the primary endpoint or mRSS and a strong trend at 48 weeks together with congruent benefit in exploratory endpoints including lung function.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.